sideroblast


Also found in: Dictionary, Thesaurus, Wikipedia.
Related to sideroblast: Myelodysplastic syndrome, ferritin

sideroblast

 [sid´er-o-blast″]
an erythroblast containing ferritin granules in its cytoplasm. adj., adj sideroblas´tic.

sid·er·o·blast

(sid'ĕr-ō-blast'),
An erythroblast containing granules of ferritin stained by the Prussian blue reaction.
[sidero- + G. blastos, germ]

sideroblast

/sid·ero·blast/ (sid´er-o-blast″) a nucleated erythrocyte containing iron granules in its cytoplasm.sideroblas´tic
ringed sideroblast  an abnormal sideroblast with many iron granules in its mitochondria, found in a ring around the nucleus; seen in sideroblastic anemia.

sideroblast

[sid′ərōblast′]
Etymology: Gk, sideros, iron, blastos, germ
an iron-rich nucleated red blood cell in the bone marrow.

sideroblast

An erythroblast with iron granules (Pappenheimer bodies) seen in bone marrow by Prussian blue or Perl stains, which highlight iron.

sid·er·o·blast

(sid'ĕr-ō-blast)
An erythroblast containing granules of ferritin stained by the Prussian blue reaction.
[sidero- + G. blastos, germ]

sideroblast

A developing red blood cell with free iron granules in its CYTOPLASM. This is normal. Iron granules in the MITOCHONDRIA and forming a ring around the nucleus are characteristic of SIDEROBLASTIC ANAEMIA.

sideroblast

a nucleated erythrocyte containing iron granules in its cytoplasm.
References in periodicals archive ?
The disease is characterized by hypochromic microcytic anemia with ring sideroblasts and early onset, nonprogressive spinocerebellar ataxia.
The postmortem findings were significant for a 90% hypercellular bone marrow with multilineage dysplasia and 15% blasts, suggesting transformation from refractory anemia with ringed sideroblasts to acute myeloid leukemia, or at least refractory anemia with excess blasts (RAEB-2).
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis.
An iron stain usually shows increased iron stores and may show ring sideroblasts (Figure 2, B [inset]).
The iron studies demonstrated adequate iron stores, and no ringed sideroblasts were seen.
DACOGEN is approved for treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System (IPSS) groups.
Patient demographics and MDS disease characteristics: Seventy-three patients; median age 73 years (range 48-89), 70% male, and WHO classification subtypes: 9 refractory anemia (RA), 11 RA with ringed sideroblasts, 4 RA with excess blasts-1, 24 refractory cytopenia with multilineage dysplasia, 14 refractory cytopenia with multilineage dysplasia with ringed sideroblasts, 4 MDS-unclassified, 2 MDS/Myeloproliferative disorder-U, 4 MDS-del 5q, and 1 unknown.
They are unusual in the morphologically low-risk subtypes of MDS, that is, refractory anemia or refractory anemia with ringed sideroblasts.
Vidaza was the first drug approved for the treatment of all five subtypes of myelodysplastic syndromes (MDS), including refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).
DACOGEN is approved, in the United States, for treatment of patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS of all French-American-British (FAB) subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, chronic myelomonocytic leukemia), and Intermediate-1, Intermediate-2 and High-Risk International Prognostic Scoring System (IPSS) groups.
Bone marrow biopsies from 23 patients showed characteristic patterns of granulocytic hypoplasia (100%), vacuolization in myeloid precursor cells, erythroid hyperplasia, increased iron staining within macrophages and plasma cells, and ringed sideroblasts.